Bientôt disponible
Pharmacology & Therapeutics
Choisissez le bon médicament, la bonne dose, et sachez pourquoi.
Le cours complet
- modules
- 83
- thèmes
- 1 081
- min par leçon
- 15
Ce que vous saurez faire.
Calculez les doses à partir de données pharmacocinétiques
Étape 1 · Drug Action & Pharmacokinetics
Repérez les interactions avant qu'elles n'atteignent le patient
Étape 2 · Safety, Evidence & Populations
Construisez des traitements pour maladies cardiaques et métaboliques
Étape 4 · Organ-System Therapeutics
Choisissez les antibiotiques en pensant au bon usage
Étape 5 · Anti-Infectives & Oncology
Révisez les ordonnances et déprescrivez en sécurité
Étape 6 · Specialist Care & Medication Safety
Traitez un cas complexe de polymédication
Étape 7 · Practicum & Capstone
Sept étapes.Une ascension continue.
Chaque grande classe de médicaments, organe par organe — puis le patient qui en prend plusieurs.
83modules
en 7 étapes
1 081thèmes
≈ 13 par module
≈270heures
en leçons de 15 minutes
≈3ans
≈18mois
≈9mois
pour finir tout le cours
- 1
Drug Action & Pharmacokinetics
Ce que fait le médicament, ce que fait le corps
13 modules · 170 thèmes · ≈ 43 h
- 2
Safety, Evidence & Populations
Quand les médicaments aident, quand ils nuisent
12 modules · 160 thèmes · ≈ 40 h
- 3
Nervous System Pharmacology
Médicaments contre douleur, humeur, sommeil et crises
14 modules · 173 thèmes · ≈ 43 h
- 4
Organ-System Therapeutics
Cœur, poumons, intestin, hormones, immunité
19 modules · 249 thèmes · ≈ 62 h
- 5
Anti-Infectives & Oncology
Combattre l'infection et le cancer
14 modules · 184 thèmes · ≈ 46 h
- 6
Specialist Care & Medication Safety
Réanimation, intoxications, prescription plus sûre
8 modules · 107 thèmes · ≈ 27 h
- 7
Practicum & Capstone
Cas réels, plusieurs médicaments à la fois
3 modules · 38 thèmes · ≈ 10 h
Mois
061218240369120246
MoisArrivée · ≈ 3 ans · ≈ 18 mois · ≈ 9 mois
Heures et mois sont des estimations : une leçon de 15 minutes par thème, chaque jour.
Chaque module.Chaque thème.
Les titres des modules et des thèmes restent en anglais, la langue du secteur.
Étape 1
Drug Action & Pharmacokinetics
Ce que fait le médicament, ce que fait le corps
13 modules · 170 thèmes
1Foundations of Pharmacology and Therapeutics11 thèmes
- Pharmacology, Clinical Pharmacology, and Pharmacotherapy
- Medicines, Active Ingredients, and Therapeutic Products
- Generic Names, Brand Names, and Drug Classifications
- Molecular Mechanisms and Clinical Effects
- Prevention, Symptom Relief, and Disease Modification
- Therapeutic Indications and Treatment Objectives
- Efficacy, Effectiveness, and Individual Benefit
- Dose, Exposure, Response, and Outcome
- Therapeutic Benefits, Harms, and Treatment Burden
- Local and Systemic Drug Actions
- Individualized Treatment and Shared Decisions
2Molecular Targets and Drug Action14 thèmes
- Receptors as Pharmacological Targets
- G Protein-Coupled Receptors
- Ligand-Gated Ion Channels
- Voltage-Gated Ion Channels
- Enzyme-Linked Receptors
- Intracellular and Nuclear Receptors
- Enzymes as Drug Targets
- Transporters, Pumps, and Carrier Proteins
- Nucleic Acids and Structural Proteins as Targets
- Orthosteric and Allosteric Binding
- Reversible and Irreversible Target Binding
- Stereoselectivity in Drug Action
- Selectivity, Specificity, and Off-Target Effects
- Drugs with Physical or Chemical Mechanisms of Action
3Quantitative Pharmacodynamics14 thèmes
- Drug Binding and Receptor Occupancy
- Affinity, Dissociation Constants, and Binding Capacity
- Graded Dose-Response Relationships
- Concentration-Response Curves
- Potency and Maximal Effect
- Full Agonists, Partial Agonists, and Inverse Agonists
- Competitive and Noncompetitive Antagonism
- Functional and Chemical Antagonism
- Receptor Reserve and Signal Amplification
- Hill Slopes and Cooperative Responses
- Quantal Dose-Response Relationships
- Therapeutic Index and Therapeutic Window
- Additivity, Synergy, and Antagonism in Drug Combinations
- Interpreting Shifts in Dose-Response Curves
4Time-Dependent Effects and Variability in Response12 thèmes
- Onset, Peak Effect, and Duration of Action
- Delayed Effects and Indirect Responses
- Receptor Desensitization and Internalization
- Receptor Upregulation and Downregulation
- Tolerance and Tachyphylaxis
- Sensitization and Cumulative Effects
- Physical Dependence and Withdrawal
- Rebound Effects After Treatment Discontinuation
- Circadian Variation and Timing of Therapy
- Disease-Related Changes in Drug Response
- Placebo, Nocebo, and Contextual Effects
- Interindividual and Intraindividual Variability
5Physicochemical Foundations of Drug Disposition11 thèmes
- Molecular Size and Membrane Permeability
- Lipid Solubility and Aqueous Solubility
- Ionization, pH, and pKa
- Applying the Henderson-Hasselbalch Relationship
- Passive Diffusion and Facilitated Transport
- Active Uptake and Efflux
- Ion Trapping Across Biological Compartments
- Dissolution and Solubility-Limited Absorption
- Protein Binding and Free Drug Concentrations
- Chemical Stability in Biological Environments
- Prodrugs and Active Metabolites
6Routes of Administration and Dosage Forms16 thèmes
- Oral Tablets, Capsules, and Liquids
- Immediate-Release and Modified-Release Formulations
- Enteric Coatings and Site-Specific Release
- Sublingual and Buccal Administration
- Intravenous, Intramuscular, and Subcutaneous Administration
- Inhaled and Intranasal Medicines
- Topical and Transdermal Delivery
- Ophthalmic and Otic Formulations
- Rectal and Vaginal Administration
- Depot Injections and Long-Acting Formulations
- Intrathecal and Other Specialized Routes
- Choosing a Route for the Therapeutic Objective
- Formulation Switching and Product Substitution
- Administration Technique as a Determinant of Exposure
- Tablet Splitting, Crushing, and Feeding-Tube Compatibility
- Injectable Medicine Compatibility, Dilution, and Stability
7Drug Absorption and Bioavailability13 thèmes
- Rate and Extent of Absorption
- Gastrointestinal pH, Motility, and Transit Time
- Food Effects on Drug Absorption
- Intestinal Uptake and Efflux Transporters
- Intestinal and Hepatic First-Pass Metabolism
- Absolute and Relative Bioavailability
- Peak Concentration and Time to Peak Concentration
- Area Under the Concentration-Time Curve
- Presystemic Loss and Extraction
- Absorption After Nonoral Administration
- Bioequivalence and Its Clinical Interpretation
- Malabsorption and Altered Gastrointestinal Anatomy
- Formulation-Dependent Differences in Exposure
8Drug Distribution12 thèmes
- Apparent Volume of Distribution
- Tissue Perfusion and Distribution Rate
- Albumin and Alpha-1-Acid Glycoprotein Binding
- Unbound and Total Drug Concentrations
- Tissue Binding and Drug Reservoirs
- Blood-Brain Barrier Penetration
- Placental Transfer and Fetal Exposure
- Distribution into Breast Milk
- Distribution into Adipose Tissue and Body Water
- Edema, Ascites, and Fluid Shifts
- Redistribution and Termination of Drug Effects
- Intracellular Accumulation and Site-of-Action Exposure
9Drug Metabolism13 thèmes
- Phase I and Phase II Biotransformation
- Cytochrome P450 Enzyme Families
- Oxidation, Reduction, and Hydrolysis
- Glucuronidation and Other Conjugation Pathways
- Extrahepatic Drug Metabolism
- Metabolic Activation of Prodrugs
- Active and Toxic Metabolites
- Enzyme Inhibition and Its Time Course
- Enzyme Induction and Its Time Course
- Saturable Metabolism and Nonlinear Exposure
- Hepatic Blood Flow and Extraction Ratio
- Enterohepatic Recirculation
- Genetic and Environmental Influences on Metabolism
10Drug Excretion and Clearance12 thèmes
- Clearance as an Organ and Whole-Body Concept
- Glomerular Filtration of Drugs
- Active Tubular Secretion
- Tubular Reabsorption and Urinary pH
- Renal Transporter-Mediated Elimination
- Biliary and Intestinal Excretion
- Pulmonary Elimination
- Renal and Nonrenal Contributions to Clearance
- Clearance of Active Metabolites
- Drug Removal by Dialysis
- Changes in Clearance During Acute Illness
- Distinguishing Elimination Rate from Clearance
11Quantitative Pharmacokinetics14 thèmes
- Concentration-Time Curves and Sampling Design
- First-Order and Capacity-Limited Elimination
- Elimination Rate Constants and Half-Life
- Relationships Among Clearance, Volume, and Half-Life
- One-Compartment Models
- Two-Compartment Models and Distribution Phases
- Intravenous Bolus and Infusion Profiles
- Extravascular Absorption Models
- Multiple Dosing and Drug Accumulation
- Steady State and Fluctuation
- Noncompartmental Pharmacokinetic Analysis
- Nonlinear Pharmacokinetics
- Population Variability and Model Assumptions
- Limits of Pharmacokinetic Parameter Estimates
12Dosage Regimens and Pharmaceutical Calculations14 thèmes
- Units, Concentrations, and Dimensional Analysis
- Mass, Volume, Moles, and Equivalents
- Percentage Strengths and Concentration Expressions
- Loading Dose Calculations
- Maintenance Dose Calculations
- Dosing Intervals and Peak-Trough Fluctuation
- Infusion Rate Calculations
- Weight-Based and Body-Surface-Area-Based Dosing
- Actual, Ideal, and Adjusted Body Weight
- Dose Adjustments for Changes in Clearance
- Oral-to-Intravenous Conversion Principles
- Cumulative Exposure and Maximum Dose Checks
- Rounding, Precision, and Independent Calculation Checks
- Detecting Unit and Decimal Errors
13Exposure-Response Relationships and Therapeutic Drug Monitoring14 thèmes
- Linking Pharmacokinetics to Pharmacodynamics
- Plasma Concentrations and Effect-Site Concentrations
- Exposure-Response and Exposure-Toxicity Relationships
- Peak, Trough, and AUC-Based Monitoring
- Selecting Medicines for Therapeutic Drug Monitoring
- Sampling Time and Interpretation of Results
- Steady-State and Non-Steady-State Samples
- Interpreting Total and Unbound Drug Levels
- Active Metabolites in Concentration Monitoring
- Bayesian Dose Adjustment Concepts
- Biomarkers of Drug Effect and Toxicity
- Investigating Unexpected Drug Concentrations
- Clinical Response When Concentrations Are Within Range
- Integrating Laboratory Results with Treatment Decisions
Étape 2
Safety, Evidence & Populations
Quand les médicaments aident, quand ils nuisent
12 modules · 160 thèmes
14Drug Interactions15 thèmes
- Pharmacokinetic and Pharmacodynamic Interactions
- Changes in Absorption and Gastric pH
- Chelation and Binding in the Gastrointestinal Tract
- Metabolic Enzyme Inhibition and Induction
- Drug Transporter Interactions
- Protein-Binding Interactions and Their Clinical Relevance
- Additive Sedation and Respiratory Depression
- Additive Bleeding and Electrolyte Risks
- QT-Prolonging Drug Combinations
- Serotonergic and Anticholinergic Burden
- Drug-Food and Drug-Alcohol Interactions
- Interactions with Herbal and Nutritional Products
- Interaction Onset, Persistence, and Offset
- Evaluating Interaction Severity and Evidence
- Avoidance, Substitution, Separation, and Monitoring Strategies
15Adverse Drug Reactions and Hypersensitivity13 thèmes
- Adverse Events and Adverse Drug Reactions
- Dose-Related and Unpredictable Reactions
- Immediate and Delayed Drug Hypersensitivity
- Immune and Nonimmune Drug Reactions
- Anaphylaxis as a Medication-Related Emergency
- Severe Cutaneous Adverse Reactions
- Cross-Reactivity and Class Effects
- Drug Allergy, Intolerance, and Side Effects
- Timing, Dechallenge, and Rechallenge Evidence
- Causality Assessment and Competing Explanations
- Documenting Reaction Phenotypes and Severity
- Allergy Evaluation and Delabeling Principles
- Avoiding Re-Exposure After Serious Reactions
16Organ Toxicity and Medication-Related Syndromes14 thèmes
- Drug-Induced Liver Injury
- Drug-Induced Kidney Injury
- Drug-Induced Arrhythmias and QT Prolongation
- Medication-Related Heart Failure and Vascular Injury
- Pulmonary Toxicity
- Bone Marrow Suppression and Cytopenias
- Ototoxicity and Ocular Toxicity
- Peripheral Neuropathy and Central Neurotoxicity
- Drug-Induced Myopathy and Rhabdomyolysis
- Serotonin Syndrome and Neuroleptic Malignant Syndrome
- Medication-Related Endocrine and Metabolic Disturbances
- Teratogenicity and Reproductive Toxicity
- Baseline Risk Assessment and Organ-Specific Monitoring
- Reversibility, Persistence, and Cumulative Toxicity
17Drug Information and Therapeutic Evidence14 thèmes
- Reading Prescribing Information and Product Monographs
- Indications, Contraindications, Warnings, and Precautions
- Using Formularies and Independent Drug References
- Interpreting Clinical Practice Guidelines
- Patient-Relevant and Surrogate Outcomes
- Relative Effects, Absolute Effects, and Baseline Risk
- Numbers Needed to Treat and Harm
- Confidence Intervals and Clinical Importance
- Applicability of Trial Results to an Individual Patient
- Comparative Effectiveness and Active Comparators
- Interpreting Subgroup and Post Hoc Findings
- Recognizing Publication Bias and Promotional Claims
- Off-Label Use and the Strength of Supporting Evidence
- Reconciling Conflicting or Changing Recommendations
18Rational Prescribing and Treatment Planning14 thèmes
- Defining the Problem That Requires Treatment
- Setting Measurable Therapeutic Goals
- Considering Nonpharmacological Alternatives and Adjuncts
- Selecting a Drug Class and Individual Medicine
- Comparing Benefit, Harm, Convenience, and Cost
- Checking Comorbidities, Contraindications, and Interactions
- Choosing Dose, Route, Frequency, and Duration
- Writing Clear and Complete Medication Orders
- Planning Baseline Tests and Follow-Up
- Defining Response, Failure, and Stopping Criteria
- Starting, Titrating, Switching, and Combining Medicines
- Rescue Therapy and Maintenance Therapy
- Communicating Uncertainty and Patient Preferences
- Documenting the Rationale for Treatment
19Medication Histories, Communication, and Adherence13 thèmes
- Constructing a Complete Medication History
- Including Nonprescription Medicines and Supplements
- Verifying What the Patient Actually Takes
- Identifying Duplicate Ingredients and Therapeutic Duplication
- Intentional and Unintentional Nonadherence
- Financial, Cognitive, Physical, and Practical Barriers
- Explaining Expected Benefits and Time to Response
- Communicating Common and Serious Adverse Effects
- Teach-Back and Accessible Medication Instructions
- Simplifying Regimens and Aligning Dosing Schedules
- Missed Doses and Product-Specific Advice
- Supporting Caregivers and Shared Medication Decisions
- Reviewing Adherence Before Escalating Therapy
20Pharmacogenetics in Drug Therapy13 thèmes
- Genetic Contributions to Pharmacokinetic Variability
- Genetic Contributions to Pharmacodynamic Variability
- Genotype, Predicted Phenotype, and Observed Response
- Poor, Intermediate, Normal, Rapid, and Ultrarapid Metabolism
- CYP2D6 and CYP2C19 Drug-Response Examples
- TPMT and NUDT15 in Thiopurine Therapy
- DPYD and Fluoropyrimidine Toxicity
- HLA-Associated Drug Hypersensitivity
- Transporter Variants and Drug Exposure
- Phenoconversion Caused by Interacting Medicines
- Applying Validated Drug-Gene Guidance
- Limits of Association Tables and Commercial Reports
- Integrating Genetic Results with Clinical Monitoring
21Biologics and Advanced Therapeutic Modalities14 thèmes
- Small Molecules and Biological Medicines
- Therapeutic Proteins, Peptides, and Enzymes
- Monoclonal Antibodies and Antibody Fragments
- Target-Mediated Drug Disposition
- Fc-Mediated Effects and Antibody Half-Life
- Immunogenicity and Antidrug Antibodies
- Biosimilars and Product-Specific Substitution Rules
- Antisense Oligonucleotides and RNA Interference
- Messenger RNA as a Therapeutic Platform
- Gene Addition and Gene Editing as Treatment Modalities
- Cell-Based Medicines and Persistence of Effect
- Delivery, Tissue Access, and Durability Limitations
- Infusion Reactions and Modality-Specific Toxicities
- Long-Term Monitoring of Advanced Therapies
22Pharmacotherapy During Pregnancy and Lactation12 thèmes
- Maternal Pharmacokinetic Changes During Pregnancy
- Gestational Timing and Fetal Susceptibility
- Placental Exposure and Drug Selection
- Balancing Untreated Disease and Treatment Risks
- Evaluating Human Pregnancy Safety Evidence
- Preconception Medication Review
- Medicines with Important Teratogenic Risks
- Treatment Changes Across Pregnancy and Postpartum
- Drug Transfer into Human Milk
- Infant Exposure and Factors Affecting Risk
- Choosing Medicines During Breastfeeding
- Counseling Under Uncertainty
23Pediatric and Neonatal Pharmacology12 thèmes
- Developmental Changes in Drug Absorption
- Age-Dependent Distribution and Protein Binding
- Maturation of Metabolism and Renal Elimination
- Neonatal and Pediatric Differences in Drug Response
- Weight-Based Dosing and Dose Limits
- Developmentally Appropriate Dosage Forms
- Excipients of Concern in Infants and Children
- Measuring and Administering Oral Liquids
- Off-Label Pediatric Use and Evidence Limitations
- Preventing Tenfold and Concentration Errors
- Monitoring Growth and Development During Therapy
- Supporting Adherence Across Childhood and Adolescence
24Geriatric Pharmacology12 thèmes
- Age-Related Changes in Drug Disposition
- Increased Pharmacodynamic Sensitivity
- Frailty and Physiological Reserve
- Multimorbidity and Competing Treatment Priorities
- Anticholinergic and Sedative Medication Burden
- Medicines Associated with Falls and Orthostatic Symptoms
- Renal Function Assessment in Older Adults
- Cognitive Impairment and Medication Management
- Potentially Inappropriate Medicines and Contextual Judgment
- Time to Benefit and Remaining Treatment Horizon
- Preventive Therapy in Advanced Frailty
- Patient Goals, Function, and Quality of Life
25Prescribing in Organ Dysfunction and Altered Physiology14 thèmes
- Selecting Renal Function Estimates for Drug Dosing
- Stable Chronic Kidney Disease and Dose Adjustment
- Acute Kidney Injury and Rapidly Changing Clearance
- Dialysis Timing and Supplemental Dosing Concepts
- Hepatic Impairment and Its Assessment Limitations
- Hypoalbuminemia and Interpretation of Drug Exposure
- Heart Failure and Altered Organ Perfusion
- Obesity and Drug-Specific Body-Size Scaling
- Cachexia, Malnutrition, and Low Body Mass
- Burns, Sepsis, and Expanded Distribution Volumes
- Augmented Renal Clearance
- Extracorporeal Circuits and Drug Sequestration
- Bariatric Surgery and Altered Oral Exposure
- Reassessing Regimens as Physiology Changes
Étape 3
Nervous System Pharmacology
Médicaments contre douleur, humeur, sommeil et crises
14 modules · 173 thèmes
26Cholinergic Pharmacology10 thèmes
- Muscarinic and Nicotinic Receptor Pharmacology
- Direct-Acting Cholinergic Agonists
- Reversible Acetylcholinesterase Inhibitors
- Irreversible Acetylcholinesterase Inhibition
- Organ-Specific Effects of Cholinergic Stimulation
- Muscarinic Antagonists and Their Selectivity
- Central and Peripheral Antimuscarinic Effects
- Therapeutic Uses of Cholinergic and Anticholinergic Drugs
- Cholinergic Excess and Anticholinergic Toxicity
- Cumulative Antimuscarinic Exposure Across Drug Classes
27Adrenergic Pharmacology12 thèmes
- Alpha and Beta Adrenoceptor Subtypes
- Catecholamine Synthesis, Storage, and Inactivation as Targets
- Direct and Indirect Sympathomimetics
- Alpha-1 and Alpha-2 Agonists
- Beta-1, Beta-2, and Beta-3 Agonists
- Mixed Adrenergic Agonists
- Selective and Nonselective Alpha Blockers
- Selective and Nonselective Beta Blockers
- Partial Agonist Activity and Additional Vasodilator Effects
- Central Sympatholytic Medicines
- Receptor Selectivity and Dose-Dependent Effects
- Withdrawal and Rebound After Adrenergic Drug Therapy
28Autacoids, Allergy, and Inflammatory Mediators12 thèmes
- Histamine Receptors and Their Pharmacological Roles
- Sedating and Less-Sedating H1 Antihistamines
- H2 Receptor Antagonists
- Leukotriene Synthesis and Receptor Inhibition
- Prostaglandins and Prostacyclin Pathways
- Bradykinin and Kallikrein-Targeted Medicines
- Mast Cell Stabilizers
- Anti-IgE and Other Targeted Allergy Treatments
- Pharmacotherapy of Allergic Rhinitis and Urticaria
- Drug Treatment of Anaphylaxis
- Pharmacological Management of Hereditary Angioedema
- Limits of Symptomatic Treatment in Allergic Emergencies
29Nonopioid Analgesics and Anti-Inflammatory Medicines12 thèmes
- Paracetamol and Acetaminophen Pharmacology
- Nonselective Cyclooxygenase Inhibitors
- Selective COX-2 Inhibitors
- Aspirin as an Analgesic and Anti-Inflammatory Drug
- Topical Nonsteroidal Anti-Inflammatory Drugs
- Gastrointestinal, Renal, and Cardiovascular NSAID Risks
- NSAID-Related Bronchospasm and Hypersensitivity
- Gastroprotection During Anti-Inflammatory Therapy
- Analgesic Selection for Acute Musculoskeletal Pain
- Analgesic Selection for Chronic Pain
- Combining Nonopioid Agents Without Ingredient Duplication
- Duration, Reassessment, and Functional Treatment Goals
30Opioids and Multimodal Pain Pharmacotherapy14 thèmes
- Opioid Receptor Subtypes and Signaling
- Full and Partial Opioid Agonists
- Opioid Antagonists and Reversal of Effects
- Immediate-Release and Extended-Release Opioids
- Analgesia, Sedation, and Respiratory Depression
- Opioid-Induced Constipation and Its Treatment
- Tolerance, Dependence, and Opioid-Induced Hyperalgesia
- Neuropathic Pain Adjuvants
- Topical Lidocaine and Capsaicin
- Combining Analgesics with Different Mechanisms
- Opioid Rotation and Incomplete Cross-Tolerance
- Risk Assessment and Monitoring During Opioid Therapy
- Tapering and Management of Withdrawal Symptoms
- Balancing Pain Relief, Function, and Treatment Burden
31Anesthesia, Sedation, and Neuromuscular Blockade14 thèmes
- Local Anesthetic Sodium Channel Blockade
- Amide and Ester Local Anesthetics
- Local Anesthetic Potency, Onset, and Duration
- Local Anesthetic Systemic Toxicity
- Inhaled General Anesthetics
- Intravenous Anesthetics and Sedative Agents
- Dissociative Anesthesia and Ketamine Pharmacology
- Benzodiazepines and Sedation Reversal
- Analgesia, Amnesia, Hypnosis, and Immobility
- Depolarizing Neuromuscular Blockers
- Nondepolarizing Neuromuscular Blockers
- Reversal of Neuromuscular Blockade
- Malignant Hyperthermia and Triggering Medicines
- Pharmacological Recovery and Residual Drug Effects
32Antiseizure Medicines12 thèmes
- Sodium Channel-Modulating Antiseizure Drugs
- Calcium Channel and Synaptic Vesicle Targets
- GABA-Enhancing Mechanisms
- Glutamatergic Targets and Other Mechanisms
- Broad-Spectrum and Seizure-Specific Treatment Choices
- Monotherapy and Rational Combination Therapy
- Enzyme-Inducing and Enzyme-Inhibiting Antiseizure Drugs
- Therapeutic Monitoring of Selected Antiseizure Medicines
- Cognitive, Behavioral, and Systemic Adverse Effects
- Antiseizure Treatment and Reproductive Considerations
- Rescue Medicines and Status Epilepticus Treatment Principles
- Treatment Withdrawal and Recurrence Risk
33Movement Disorders and Neurodegenerative Therapeutics13 thèmes
- Levodopa and Peripheral Decarboxylase Inhibitors
- Dopamine Agonists
- MAO-B and COMT Inhibitors
- Amantadine and Anticholinergic Treatments
- Wearing-Off, Dyskinesia, and Motor Fluctuations
- Neuropsychiatric Effects of Parkinsonian Medicines
- Medicines for Essential Tremor
- VMAT2 Inhibitors for Selected Movement Disorders
- Cholinesterase Inhibitors in Dementia
- Memantine and Glutamatergic Modulation
- Disease-Modifying Alzheimer Therapies and Monitoring Burden
- Pharmacological Treatment of Motor Neuron Disease
- Symptom Relief and Realistic Treatment Outcomes
34Migraine and Headache Pharmacotherapy11 thèmes
- Acute and Preventive Treatment Objectives
- Triptans and Serotonin Receptor Selectivity
- Gepants and CGRP Receptor Antagonism
- Ditans and Nonvasoconstrictive Serotonergic Therapy
- CGRP-Targeted Monoclonal Antibodies
- Established Oral Migraine Preventive Medicines
- Botulinum Toxin in Chronic Migraine
- Antiemetic Use in Migraine Treatment
- Medication-Overuse Headache
- Pharmacotherapy of Cluster Headache
- Treatment Selection with Cardiovascular and Reproductive Constraints
35Neuroimmune and Neuromuscular Pharmacotherapy11 thèmes
- Multiple Sclerosis Disease-Modifying Treatment Classes
- Immune Trafficking and Lymphocyte-Targeted Therapies
- Treatment of Acute Neuroinflammatory Relapses
- Infection Risks and Monitoring During Neuroimmune Therapy
- Symptomatic Treatment of Spasticity
- Acetylcholinesterase Inhibitors in Myasthenia Gravis
- Immunosuppressive Treatment of Neuromuscular Autoimmunity
- Complement and FcRn Inhibitors in Selected Disorders
- Immunoglobulin Therapy in Neurological Disease
- Botulinum Toxins for Focal Muscle Overactivity
- Medicines That Worsen Neuromuscular Transmission
36Antidepressants and Anxiolytic Medicines14 thèmes
- Selective Serotonin Reuptake Inhibitors
- Serotonin-Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
- Other Antidepressant Mechanisms
- Delayed Therapeutic Effects and Early Adverse Effects
- Antidepressant Selection by Symptoms and Comorbidities
- Benzodiazepines in Anxiety Treatment
- Buspirone and Other Nonbenzodiazepine Options
- Treatment Response, Remission, and Relapse Prevention
- Switching Antidepressants and Washout Requirements
- Augmentation and Treatment-Resistant Depression
- Antidepressant Discontinuation Symptoms
- Monitoring Activation, Mood Switching, and Suicide Risk
37Antipsychotics and Mood Stabilizers14 thèmes
- Dopamine Receptor Antagonism and Partial Agonism
- First-Generation and Second-Generation Antipsychotics
- Oral and Long-Acting Injectable Formulations
- Extrapyramidal Symptoms and Their Management
- Tardive Dyskinesia and Treatment Options
- Metabolic, Endocrine, and Cardiovascular Adverse Effects
- Clozapine and Required Clinical Monitoring
- Lithium Pharmacology and Concentration Monitoring
- Antiseizure Medicines Used as Mood Stabilizers
- Pharmacotherapy of Acute Mania
- Pharmacotherapy of Bipolar Depression
- Maintenance Treatment and Relapse Prevention
- Distinguishing Therapeutic Nonresponse from Inadequate Exposure
- Combined Treatment and Cumulative Adverse Effects
38Sleep, Wakefulness, and Attention Therapies11 thèmes
- Benzodiazepine Receptor Agonists for Insomnia
- Melatonin and Melatonin Receptor Agonists
- Orexin Receptor Antagonists
- Sedating Medicines and Off-Label Sleep Treatment
- Next-Day Impairment, Falls, and Complex Sleep Behaviors
- Stimulants for Attention-Deficit/Hyperactivity Disorder
- Nonstimulant ADHD Medicines
- Cardiovascular, Growth, and Psychiatric Monitoring in ADHD
- Wake-Promoting Agents for Selected Sleep Disorders
- Medicines for Narcolepsy and Cataplexy
- Dependence, Misuse, and Treatment Reassessment
39Pharmacotherapy of Substance Use Disorders13 thèmes
- Therapeutic Goals in Addiction Treatment
- Nicotine Replacement Products
- Varenicline and Bupropion for Tobacco Cessation
- Methadone and Buprenorphine in Opioid Use Disorder
- Naltrexone and Opioid Receptor Blockade
- Naloxone for Opioid Overdose Reversal
- Precipitated Withdrawal and Treatment Transitions
- Medicines for Alcohol Use Disorder
- Pharmacological Management of Alcohol Withdrawal
- Thiamine in Patients at Risk of Deficiency
- Sedative Dependence and Supervised Withdrawal Principles
- Evidence Gaps in Stimulant Use Disorder Pharmacotherapy
- Combining Medication with Psychosocial Treatment
Étape 4
Organ-System Therapeutics
Cœur, poumons, intestin, hormones, immunité
19 modules · 249 thèmes
40Antihypertensive Pharmacotherapy13 thèmes
- Renin-Angiotensin-Aldosterone System Targets
- ACE Inhibitors and Angiotensin Receptor Blockers
- Dihydropyridine Calcium Channel Blockers
- Nondihydropyridine Calcium Channel Blockers
- Thiazide and Thiazide-Like Diuretics in Hypertension
- Beta Blockers in Selected Hypertensive Patients
- Mineralocorticoid Receptor Antagonists
- Alpha Blockers, Central Agents, and Direct Vasodilators
- Initial Therapy and Combination Treatment Principles
- Hypertension with Kidney Disease, Diabetes, or Pregnancy
- Resistant Hypertension and Medication Review
- Orthostatic Hypotension and Treatment Tolerability
- Laboratory and Clinical Monitoring of Antihypertensive Therapy
41Ischemic Heart Disease Pharmacotherapy11 thèmes
- Symptom Control and Cardiovascular Event Prevention
- Organic Nitrates and Nitric Oxide Signaling
- Nitrate Tolerance and Important Drug Interactions
- Beta Blockers in Angina
- Calcium Channel Blockers in Angina
- Other Antianginal Mechanisms and Selected Uses
- Pharmacological Management of Vasospastic Angina
- Antithrombotic Treatment in Acute Coronary Syndromes
- Secondary Prevention After Myocardial Infarction
- Persistent Angina and Treatment Reassessment
- Balancing Ischemic Benefit and Bleeding Risk
42Heart Failure Pharmacotherapy14 thèmes
- Treatment Objectives Across Heart Failure Phenotypes
- ACE Inhibitors, ARBs, and Angiotensin Receptor-Neprilysin Inhibition
- Evidence-Based Beta Blockade in Heart Failure
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
- SGLT2 Inhibitors in Heart Failure
- Diuretics for Congestion Relief
- Hydralazine and Nitrate Combinations
- Ivabradine and Selected Heart Rate Reduction
- Digoxin: Selected Roles and Toxicity
- Intravenous Inotropes and Their Limitations
- Initiation, Titration, and Combination Tolerability
- Monitoring Blood Pressure, Renal Function, and Potassium
- Medicines That Can Worsen Heart Failure
- Transitioning from Acute Stabilization to Long-Term Therapy
43Antiarrhythmic Pharmacology13 thèmes
- Cardiac Ion Channels as Drug Targets
- Sodium Channel-Blocking Antiarrhythmics
- Beta Blockers for Arrhythmia Management
- Potassium Channel-Blocking Antiarrhythmics
- Rate-Limiting Calcium Channel Blockers
- Adenosine and Acute Supraventricular Tachycardia
- Amiodarone and Multiorgan Toxicity
- Rate Control and Rhythm Control Objectives
- Drug Selection in Structural Heart Disease
- QT Prolongation and Torsades de Pointes Risk
- Proarrhythmia and Electrolyte Interactions
- Antiarrhythmic Loading, Accumulation, and Monitoring
- Bradycardia, Conduction Block, and Treatment Interactions
44Lipid-Lowering and Atherosclerotic Risk Reduction11 thèmes
- Statins and HMG-CoA Reductase Inhibition
- Ezetimibe and Intestinal Cholesterol Absorption
- PCSK9-Targeted Antibodies and RNA-Based Therapy
- Bempedoic Acid and ATP Citrate Lyase Inhibition
- Bile Acid Sequestrants
- Fibrates and Triglyceride-Lowering Therapy
- Prescription Omega-3 Products and Product-Specific Evidence
- Selecting Treatment by Cardiovascular Risk and Lipid Pattern
- Muscle Symptoms, Liver Tests, and Drug Interactions
- Statin Intolerance and Alternative Treatment Strategies
- Combination Therapy and Follow-Up Lipid Assessment
45Antiplatelet, Anticoagulant, and Fibrinolytic Medicines16 thèmes
- Aspirin and Irreversible Platelet Cyclooxygenase Inhibition
- P2Y12 Receptor Inhibitors
- Other Platelet-Targeted Medicines
- Unfractionated and Low-Molecular-Weight Heparins
- Fondaparinux and Indirect Factor Xa Inhibition
- Vitamin K Antagonists
- Direct Oral Anticoagulants
- Parenteral Direct Thrombin Inhibitors
- Fibrinolytic Drugs and Their Therapeutic Contexts
- Antifibrinolytic Medicines
- Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
- Laboratory Monitoring and Assay Limitations
- Bleeding Management and Anticoagulant Reversal
- Heparin-Induced Thrombocytopenia
- Periprocedural Interruption and Bridging Decisions
- Duration, Combination Therapy, and Reassessment of Bleeding Risk
46Diuretics and Renal Pharmacotherapy13 thèmes
- Nephron Sites of Diuretic Action
- Loop Diuretics
- Thiazide and Thiazide-Like Diuretics
- Potassium-Sparing Diuretics
- Carbonic Anhydrase Inhibitors
- Osmotic Diuretics
- Vasopressin Receptor Antagonists
- Diuretic Resistance and Sequential Nephron Blockade
- Monitoring Volume Status and Electrolyte Loss
- Pharmacological Kidney Protection in Chronic Disease
- Medicines for Complications of Chronic Kidney Disease
- Drug-Induced Changes in Creatinine Without Reduced Filtration
- Avoiding Nephrotoxic Combinations
47Fluids, Electrolytes, and Acid-Base Therapies13 thèmes
- Crystalloid Solutions and Their Composition
- Colloid Solutions and Clinical Limitations
- Maintenance, Replacement, and Resuscitation Objectives
- Sodium Disorders and Controlled Correction Principles
- Potassium Replacement and Administration Risks
- Pharmacological Management of Hyperkalemia
- Magnesium and Calcium Replacement
- Phosphate Replacement
- Bicarbonate and Other Alkalinizing Therapies
- Oral Rehydration Formulations
- Glucose-Containing Fluids and Metabolic Effects
- Fluid Overload and Treatment Reassessment
- Monitoring During Intravenous Fluid and Electrolyte Therapy
48Respiratory Pharmacotherapy14 thèmes
- Short-Acting and Long-Acting Beta-2 Agonists
- Short-Acting and Long-Acting Muscarinic Antagonists
- Inhaled Corticosteroids
- Combination Inhalers and Regimen Selection
- Leukotriene Modifiers in Airway Disease
- Biologic Therapies for Severe Asthma
- Systemic Corticosteroids in Respiratory Exacerbations
- Phosphodiesterase Inhibitors and Other Selected COPD Therapies
- Reliever and Controller Treatment Strategies
- Inhaler Technique, Adherence, and Local Adverse Effects
- Antifibrotic Medicines for Selected Interstitial Lung Diseases
- Pulmonary Arterial Hypertension Drug Classes
- CFTR Modulators and Disease-Specific Respiratory Therapy
- Cough Medicines, Mucolytics, and Evidence Limitations
49Acid-Related Disorders, Nausea, and Gastric Motility13 thèmes
- Proton Pump Inhibitors
- Histamine H2 Receptor Blockade
- Antacids, Alginates, and Mucosal Protectants
- Gastroesophageal Reflux Pharmacotherapy
- Peptic Ulcer Treatment and Helicobacter pylori Eradication Principles
- Stress Ulcer Prophylaxis and Appropriate Selection
- Serotonin 5-HT3 Receptor Antagonists
- Dopamine Antagonists and Prokinetic Medicines
- Neurokinin-1 Receptor Antagonists
- Antihistamine and Antimuscarinic Antiemetics
- Antiemetic Combinations by Clinical Setting
- Gastroparesis Treatment and Limitations
- Long-Term Acid Suppression and Deprescribing
50Intestinal, Pancreatic, and Hepatic Pharmacotherapy13 thèmes
- Bulk-Forming, Osmotic, and Stimulant Laxatives
- Intestinal Secretagogues and Motility-Targeted Medicines
- Antidiarrheal Medicines and Their Contraindications
- Pharmacological Treatment of Irritable Bowel Syndrome
- Aminosalicylates in Inflammatory Bowel Disease
- Corticosteroid Induction and Steroid-Sparing Maintenance
- Biologic and Targeted Small-Molecule IBD Therapies
- Pancreatic Enzyme Replacement
- Bile Acid-Targeted Medicines
- Pharmacological Treatment of Hepatic Encephalopathy
- Medicines for Portal Hypertension and Variceal Bleeding
- Ascites Pharmacotherapy and Monitoring
- Therapeutic Limitations in Advanced Liver Disease
51Diabetes Pharmacotherapy15 thèmes
- Insulin Preparations and Time-Action Profiles
- Basal, Prandial, and Correction Insulin Concepts
- Insulin Administration and Concentration Safety
- Metformin and Hepatic Glucose Production
- Sulfonylureas and Meglitinides
- Thiazolidinediones
- DPP-4 Inhibitors
- GLP-1 Receptor Agonists and Dual Incretin Agonists
- SGLT2 Inhibitors
- Alpha-Glucosidase Inhibitors and Other Selected Agents
- Selecting Therapy for Glycemic and Cardiorenal Goals
- Hypoglycemia Risk and Rescue Medicines
- Sick-Day Medication Management Principles
- Treatment Intensification and Deintensification
- Monitoring Efficacy, Weight, Renal Function, and Adverse Effects
52Obesity and Weight-Management Pharmacotherapy11 thèmes
- Indications and Goals of Weight-Management Medicines
- Appetite, Satiety, and Energy Intake as Drug Targets
- Incretin-Based Weight-Management Therapies
- Centrally Acting Anti-Obesity Medicines
- Gastrointestinal Lipase Inhibition
- Treatment Selection with Psychiatric and Cardiovascular Comorbidities
- Tolerability, Nutritional Intake, and Lean-Mass Considerations
- Assessing Response and Criteria for Continuing Treatment
- Weight Recurrence After Discontinuation
- Interactions with Other Long-Term Medicines
- Product Quality and Risks of Unverified Preparations
53Thyroid, Adrenal, and Pituitary Pharmacology15 thèmes
- Thyroid Hormone Replacement
- Thionamides and Thyroid Hormone Synthesis Inhibition
- Iodide and Radioiodine in Selected Thyroid Treatments
- Monitoring and Interactions in Thyroid Therapy
- Glucocorticoid Receptor Pharmacology
- Mineralocorticoid Replacement
- Systemic Corticosteroid Potency and Duration
- Hypothalamic-Pituitary-Adrenal Suppression
- Corticosteroid Tapering and Stress Coverage Principles
- Steroidogenesis Inhibitors and Cortisol Receptor Antagonism
- Growth Hormone and Growth Hormone Antagonists
- Somatostatin Analogs
- Dopamine Agonists for Hyperprolactinemia
- Vasopressin Analogs and Desmopressin
- Endocrine Replacement Monitoring and Overtreatment
54Reproductive and Sexual Health Pharmacotherapy14 thèmes
- Estrogens, Progestogens, and Their Receptor Effects
- Combined and Progestogen-Only Contraceptives
- Long-Acting Contraceptive Drug Formulations
- Emergency Contraceptive Medicines
- Drug Interactions That Affect Contraceptive Efficacy
- Menopausal Hormone Therapy and Individual Risk Assessment
- Androgen Replacement and Antiandrogens
- GnRH Agonists and Antagonists
- Pharmacological Ovulation Induction
- Medicines for Endometriosis and Heavy Menstrual Bleeding
- Uterotonic and Tocolytic Medicines
- Pharmacology of Medication Abortion
- Medicines for Erectile Dysfunction
- Reproductive Counseling for Teratogenic Medicines
55Urological Pharmacotherapy10 thèmes
- Alpha-1 Blockers for Lower Urinary Tract Symptoms
- 5-Alpha-Reductase Inhibitors
- Combination Treatment for Benign Prostatic Enlargement
- Antimuscarinic Medicines for Overactive Bladder
- Beta-3 Agonists for Overactive Bladder
- Intravesical Botulinum Toxin Pharmacology
- Selected Drug Treatment of Nocturia
- Medicines Used in Urinary Stone Prevention
- Urinary Retention and Medication-Related Symptoms
- Monitoring Blood Pressure, Cognition, and Urinary Effects
56Bone and Mineral Metabolism Therapies13 thèmes
- Calcium and Vitamin D Preparations
- Active Vitamin D Analogs
- Bisphosphonates
- RANKL Inhibition
- Parathyroid Hormone Receptor Agonists
- Sclerostin Inhibition
- Selective Estrogen Receptor Modulators
- Calcimimetics
- Phosphate Binders
- Antiresorptive and Anabolic Treatment Sequencing
- Hypocalcemia, Jaw Osteonecrosis, and Atypical Fracture Risks
- Treatment Interruption and Rebound Bone Loss
- Monitoring Skeletal Treatment Response
57Rheumatology and Immune-Mediated Inflammatory Disease14 thèmes
- Conventional Synthetic Disease-Modifying Antirheumatic Drugs
- Methotrexate Pharmacology and Weekly-Dosing Safety
- Antimalarial Medicines in Autoimmune Disease
- TNF Inhibitors
- Interleukin-Targeted Therapies
- B-Cell-Directed and T-Cell Costimulation Therapies
- Janus Kinase Inhibitors
- Treat-to-Target and Steroid-Sparing Strategies
- Screening and Monitoring Before Immunomodulatory Therapy
- Infection, Malignancy, and Thrombotic Risk Assessment
- Medicines for Acute Gout Flares
- Xanthine Oxidase Inhibitors and Uricosurics
- Urate-Lowering Initiation, Prophylaxis, and Monitoring
- Switching Mechanisms After Inadequate Response
58Transplantation and Systemic Immunosuppression13 thèmes
- Calcineurin Inhibitors
- Antimetabolite Immunosuppressants
- mTOR Inhibitors
- Corticosteroids in Transplant Regimens
- Lymphocyte-Depleting and Nondepleting Antibodies
- Costimulation Blockade
- Induction, Maintenance, and Rejection Treatment Objectives
- Immunosuppressant Concentration Monitoring
- Interactions with Anti-Infective Medicines
- Infection Prophylaxis During Immunosuppression
- Nephrotoxicity, Metabolic Effects, and Malignancy Risk
- Adherence and Consequences of Interrupted Treatment
- Balancing Graft Protection and Treatment Toxicity
Étape 5
Anti-Infectives & Oncology
Combattre l'infection et le cancer
14 modules · 184 thèmes
59Principles of Anti-Infective Pharmacology14 thèmes
- Selective Toxicity and Antimicrobial Targets
- Spectrum of Activity and Clinical Coverage
- Bactericidal and Bacteriostatic Activity in Context
- Minimum Inhibitory Concentrations and Susceptibility Categories
- Time-Dependent and Concentration-Dependent Activity
- AUC-to-MIC and Other Exposure Targets
- Post-Antibiotic Effects
- Tissue Penetration and Infection-Site Exposure
- Inoculum, Biofilms, and Limits of Drug Activity
- Intrinsic and Acquired Resistance Relevant to Treatment
- Combination Therapy, Synergy, and Antagonism
- Host Factors That Change Anti-Infective Selection
- Prophylactic, Empiric, and Targeted Treatment
- Source Control as a Requirement for Effective Therapy
60Beta-Lactams and Other Cell Wall-Active Antibiotics13 thèmes
- Penicillins and Their Antibacterial Spectra
- Cephalosporin Families and Spectrum Differences
- Carbapenems
- Monobactams
- Beta-Lactamase Inhibitors
- Beta-Lactam and Beta-Lactamase Inhibitor Combinations
- Penicillin-Binding Proteins and Resistance
- Glycopeptides and Lipoglycopeptides
- Fosfomycin and Other Cell Wall-Active Agents
- Beta-Lactam Allergy and Cross-Reactivity Assessment
- Infusion Strategies and Pharmacodynamic Exposure
- Renal Adjustment and Neurotoxicity Risks
- Monitoring Glycopeptide Exposure and Toxicity
61Other Antibacterial Drug Classes14 thèmes
- Aminoglycosides
- Macrolides and Ketolides
- Tetracyclines and Related Agents
- Lincosamides
- Oxazolidinones
- Fluoroquinolones
- Folate Antagonists and Combination Therapy
- Nitroimidazoles
- Nitrofurantoin and Urinary Antibacterial Activity
- Lipopeptides and Membrane-Active Antibiotics
- Polymyxins and Toxicity Limitations
- Rifamycins and Major Drug Interactions
- Class-Specific Resistance and Cross-Resistance
- Comparing Major Toxicities Across Antibacterial Classes
62Antibacterial Therapeutics and Stewardship16 thèmes
- Choosing Empiric Therapy for the Clinical Syndrome
- Incorporating Local Susceptibility Information
- Antibiotic Selection for Respiratory Infections
- Antibiotic Selection for Urinary Tract Infections
- Antibiotic Selection for Skin and Soft Tissue Infections
- Antibiotic Selection for Intra-Abdominal Infections
- Treatment Principles for Bloodstream and Endovascular Infections
- Central Nervous System Infection and Drug Penetration
- Antibacterial Treatment in Immunocompromised Patients
- Surgical and Procedure-Related Antibiotic Prophylaxis
- Culture-Guided De-Escalation
- Intravenous-to-Oral Switching
- Choosing and Reassessing Treatment Duration
- Clostridioides difficile-Associated Disease and Drug Selection
- WHO AWaRe Categories and Responsible Antibiotic Use
- Distinguishing Colonization from a Treatment Indication
63Antimycobacterial Pharmacotherapy11 thèmes
- Isoniazid, Rifamycins, Pyrazinamide, and Ethambutol
- Why Active Tuberculosis Requires Combination Treatment
- Drug-Susceptible and Drug-Resistant Treatment Principles
- Fluoroquinolones in Selected Mycobacterial Regimens
- Bedaquiline, Pretomanid, and Other Specialized Agents
- Mycobacterial Treatment Toxicities and Monitoring
- Rifamycin Interactions and Regimen Compatibility
- Preventive Treatment for Latent Tuberculosis Infection
- Treatment Adherence and Consequences of Interruption
- Nontuberculous Mycobacterial Drug Treatment
- Antileprosy Medicines
64Antifungal Pharmacology and Therapeutics13 thèmes
- Polyene Antifungals
- Azole Antifungals
- Echinocandins
- Flucytosine
- Allylamines and Other Superficial Antifungals
- Superficial, Mucosal, and Invasive Treatment Objectives
- Candida Infection and Drug Selection
- Aspergillus and Other Invasive Mold Infections
- Cryptococcal Treatment Principles
- Antifungal Prophylaxis in Selected High-Risk Patients
- Antifungal Drug Interactions and Liver Toxicity
- Therapeutic Monitoring of Selected Antifungals
- Resistance, Tissue Penetration, and Treatment Failure
65Antiviral Pharmacology and Therapeutics15 thèmes
- Viral Entry, Replication, and Maturation as Drug Targets
- Antiherpesvirus Nucleoside Analogs
- Cytomegalovirus-Directed Medicines
- Influenza Antivirals
- Coronavirus-Directed Antivirals and Interaction Assessment
- HIV Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors
- HIV Integrase and Protease Inhibitors
- HIV Entry, Fusion, and Capsid Inhibitors
- Combination Antiretroviral Therapy and Resistance Prevention
- Long-Acting Antiretroviral Formulations
- Hepatitis B Antiviral Therapy
- Direct-Acting Hepatitis C Antivirals
- Preexposure and Postexposure Antiviral Prophylaxis
- Renal, Bone, Metabolic, and Hepatic Monitoring
- Adherence, Drug Interactions, and Virological Failure
66Antiparasitic Pharmacotherapy12 thèmes
- Antimalarial Drug Classes and Parasite-Stage Activity
- Combination Antimalarial Treatment Principles
- Malaria Chemoprophylaxis and Resistance Considerations
- Radical Cure, Hypnozoites, and G6PD-Related Drug Risk
- Medicines for Amoebiasis and Giardiasis
- Pharmacotherapy of Toxoplasmosis
- Medicines for Leishmaniasis and Trypanosomiasis
- Benzimidazole Anthelmintics
- Ivermectin and Related Antiparasitic Uses
- Praziquantel and Other Selected Anthelmintics
- Ectoparasiticides
- Pregnancy, Organ Function, and Parasite-Specific Treatment Constraints
67Vaccines and Passive Immunoprophylaxis12 thèmes
- Live Attenuated and Inactivated Vaccines
- Protein, Polysaccharide, and Conjugate Vaccines
- Viral Vector and Nucleic Acid Vaccine Platforms
- Adjuvants and Immune Response Enhancement
- Primary Series, Boosters, and Waning Protection
- Passive Immunization with Immunoglobulins
- Monoclonal Antibodies for Infection Prevention
- Preexposure and Postexposure Immunoprophylaxis
- Contraindications and Precautions for Vaccine Products
- Vaccination During Immunosuppressive Treatment
- Reactogenicity and Suspected Vaccine Adverse Reactions
- Storage, Handling, and Product-Specific Administration Requirements
68Cytotoxic Anticancer Pharmacology13 thèmes
- Cell Cycle Dependence and Cytotoxic Drug Action
- Alkylating Agents
- Platinum Compounds
- Antimetabolites and Folate Pathway Inhibitors
- Purine and Pyrimidine Analogs
- Anthracyclines and Other Antitumor Antibiotics
- Topoisomerase Inhibitors
- Microtubule-Targeted Medicines
- Combination Regimens and Nonoverlapping Toxicities
- Treatment Cycles, Dose Intensity, and Recovery
- Myelosuppression and Cumulative Organ Toxicity
- Resistance to Cytotoxic Treatment
- Dose Modification for Organ Dysfunction and Toxicity
69Targeted and Endocrine Anticancer Therapy14 thèmes
- Kinase Inhibitors and Oncogenic Signaling
- Growth Factor Receptor-Targeted Antibodies
- Angiogenesis Inhibitors
- PARP Inhibitors and DNA Repair Vulnerabilities
- CDK Inhibitors and Cell Cycle Targets
- Proteasome Inhibitors and Selected Epigenetic Therapies
- Antibody-Drug Conjugates
- Estrogen Receptor Modulators and Degraders
- Aromatase Inhibitors
- Androgen Deprivation and Androgen Receptor Pathway Inhibitors
- Biomarker Eligibility for Drug Selection
- Acquired Resistance and Treatment Sequencing
- Oral Anticancer Drug Interactions and Adherence
- Target-Specific Toxicity Monitoring
70Cancer Immunotherapy and Cellular Therapies12 thèmes
- Immune Checkpoint Inhibitors
- T-Cell-Engaging Bispecific Antibodies
- CAR T-Cell and Other Adoptive Cellular Therapies
- Cytokine-Based Anticancer Medicines
- Therapeutic Cancer Vaccines and Oncolytic Approaches
- Immune Activation and Delayed Treatment Effects
- Immune-Related Adverse Events
- Cytokine Release Syndrome
- Immune Effector Cell-Associated Neurotoxicity
- Pharmacological Management of Treatment-Related Immune Toxicity
- Infection Prophylaxis and Prolonged Cytopenias
- Persistence, Retreatment, and Long-Term Follow-Up
71Supportive Pharmacotherapy in Cancer Care12 thèmes
- Antiemetic Regimens by Emetogenic Risk
- Hematopoietic Growth Factors
- Prevention and Treatment of Tumor Lysis Syndrome
- Uroprotection and Other Cytoprotective Medicines
- Anticancer Drug Extravasation and Antidote Selection
- Management of Treatment-Related Diarrhea and Mucositis
- Cancer-Associated Thrombosis
- Medicines for Bone Metastases and Hypercalcemia
- Cancer Pain and Breakthrough Symptoms
- Infection Prophylaxis During Myelosuppressive Treatment
- Reproductive Risks and Fertility-Related Medication Counseling
- Supportive Care Interactions with Anticancer Regimens
72Hematological Pharmacotherapy13 thèmes
- Oral and Intravenous Iron Preparations
- Vitamin B12 and Folate Replacement
- Erythropoiesis-Stimulating Agents
- Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
- Thrombopoietin Receptor Agonists
- Hemostatic Factor Replacement Products
- Nonfactor Therapies for Hemophilia
- Medicines for Immune Thrombocytopenia
- Complement Inhibitors in Selected Hematological Disorders
- Disease-Modifying Medicines for Sickle Cell Disease
- Iron Chelation in Chronic Iron Overload
- Balancing Hematological Response and Thrombotic Risk
- Monitoring Blood Counts, Iron Status, and Treatment Toxicity
Étape 6
Specialist Care & Medication Safety
Réanimation, intoxications, prescription plus sûre
8 modules · 107 thèmes
73Dermatological Pharmacotherapy13 thèmes
- Skin Penetration and Topical Vehicle Selection
- Topical Corticosteroid Potency and Site of Use
- Topical Calcineurin and PDE4 Inhibitors
- Topical and Systemic Retinoids
- Acne Treatment Combinations and Antibiotic Stewardship
- Pharmacotherapy of Atopic Dermatitis
- Topical and Systemic Psoriasis Treatments
- Rosacea Pharmacotherapy
- Antifungal and Antiparasitic Skin Treatments
- Keratolytics, Emollients, and Barrier Therapies
- Medicines for Alopecia and Selected Pigment Disorders
- Photosensitivity and Drug-Related Skin Injury
- Monitoring Systemic Absorption from Topical Products
74Ophthalmic and Otic Pharmacotherapy13 thèmes
- Ocular Drug Delivery and Systemic Absorption
- Prostaglandin Analogs for Glaucoma
- Ocular Beta Blockers and Alpha Agonists
- Ocular Carbonic Anhydrase and Rho Kinase Inhibitors
- Mydriatic and Cycloplegic Medicines
- Ocular Anti-Inflammatory and Antiallergic Medicines
- Ophthalmic Antimicrobial Treatment
- Intravitreal Anti-VEGF Medicines
- Lubricants and Medicines for Dry Eye Disease
- Ocular Toxicity from Systemic Medicines
- Otic Anti-Infective and Anti-Inflammatory Products
- Tympanic Membrane Integrity and Otic Drug Selection
- Safe Use of Ophthalmic and Otic Formulations
75Emergency, Critical Care, and Perioperative Pharmacotherapy15 thèmes
- Vasopressors and Inotropes in Shock
- Choosing Hemodynamic Drug Targets
- Analgesia and Sedation in Critical Illness
- Medicines Used During Resuscitation
- Pharmacological Treatment of Hypertensive Emergencies
- Time-Critical Antithrombotic and Thrombolytic Treatment
- Drug Management of Severe Hypoglycemia and Hyperglycemic Crises
- Acute Adrenal and Thyroid Emergencies
- Emergency Reversal of Medication Effects
- Perioperative Continuation and Withholding of Chronic Medicines
- Thromboprophylaxis in Hospitalized Patients
- Pharmacological Components of Parenteral Nutrition
- Prevention and Management of Refeeding-Related Electrolyte Problems
- Infusion Titration, Compatibility, and Monitoring
- Reassessment as Organ Function and Clinical Status Change
76Clinical Toxicology and Antidotes15 thèmes
- Exposure History and Toxicological Risk Assessment
- Toxidromes and Their Pharmacological Basis
- Dose, Time, Formulation, and Delayed Toxicity
- Supportive Care as a Foundation of Poisoning Management
- Activated Charcoal and Its Limitations
- Enhanced Elimination and Extracorporeal Treatment Principles
- Acetaminophen Poisoning and N-Acetylcysteine
- Opioid Toxicity and Antagonist Treatment
- Salicylate and Lithium Toxicity
- Digoxin Toxicity and Antibody Fragments
- Toxic Alcohols and Alcohol Dehydrogenase Inhibition
- Cholinesterase Inhibitor Poisoning and Antidotal Therapy
- Selected Metal Poisonings and Chelation
- Antidote Adverse Effects and Monitoring
- Poison Information Services and Specialist Consultation
77Palliative and End-of-Life Pharmacotherapy13 thèmes
- Aligning Medicines with Comfort and Patient Goals
- Pain Treatment in Advanced Illness
- Pharmacological Relief of Breathlessness
- Treatment of Nausea and Vomiting in Palliative Care
- Constipation and Opioid-Related Bowel Dysfunction
- Medicines for Excess Respiratory Secretions
- Pharmacological Management of Agitation and Delirium
- Anxiety and Sleep Symptoms in Advanced Illness
- Alternative Routes When Swallowing Is Impaired
- Organ Failure and Drug Accumulation Near the End of Life
- Anticipatory Prescribing and Rescue Medicines
- Proportional Symptom Relief and Palliative Sedation Principles
- Reviewing Preventive Medicines with Limited Near-Term Benefit
78Nonprescription Medicines and Complementary Products12 thèmes
- Appropriate Scope of Nonprescription Treatment
- Reading Active Ingredients and Product Labels
- Combination Cold, Cough, and Allergy Products
- Nonprescription Analgesics and Duplicate Exposure
- Antacids, Laxatives, and Short-Term Symptom Treatments
- Vitamins and Minerals: Replacement and Excess
- Herbal Products with Pharmacological Activity
- Herb-Drug and Supplement-Drug Interactions
- Variable Composition, Contamination, and Adulteration
- Evaluating Therapeutic Claims and Evidence Quality
- Self-Treatment in Pregnancy, Childhood, and Older Age
- Persistent Symptoms and Limits of Self-Care
79Medication Safety and Pharmacovigilance12 thèmes
- Medication Errors, Adverse Reactions, and Preventable Harm
- High-Alert Medicines and Error-Prone Situations
- Look-Alike and Sound-Alike Medicine Names
- Prescribing, Dispensing, and Administration Errors
- Concentration, Route, and Formulation Mix-Ups
- Independent Checks and Safe Medication Communication
- Reporting Suspected Adverse Drug Reactions
- Postmarketing Safety Signals and Their Limitations
- Interpreting Safety Alerts and Label Changes
- Medication Incidents and Contributing System Factors
- Patient Involvement in Detecting Medication Problems
- Applying Safety Findings to Individual Treatment Plans
80Medication Review, Deprescribing, and Transitions of Care14 thèmes
- Matching Every Medicine to a Current Indication
- Identifying Prescribing Cascades
- Therapeutic Duplication and Conflicting Treatment Goals
- Assessing Cumulative Sedative, Anticholinergic, and Bleeding Risks
- Prioritizing Medicines for Review
- Time-Limited Treatment Trials
- Distinguishing Withdrawal from Disease Recurrence
- Selecting a Tapering or Direct Discontinuation Strategy
- Monitoring After Dose Reduction or Withdrawal
- Reconciliation at Admission, Transfer, and Discharge
- Communicating Reasons for Medication Changes
- Preventing Unintended Continuation of Temporary Medicines
- Follow-Up Responsibility and Continuity of Supply
- Negotiating Treatment Changes with Patients and Caregivers
Étape 7
Practicum & Capstone
Cas réels, plusieurs médicaments à la fois
3 modules · 38 thèmes
81Clinical Pharmacology Calculation and Monitoring Practicum11 thèmes
- Interpreting an Unfamiliar Drug Concentration-Time Profile
- Comparing Exposure Across Formulations
- Calculating a Loading and Maintenance Regimen
- Adjusting a Regimen After a Change in Renal Function
- Investigating an Unexpectedly High Trough Concentration
- Interpreting Drug Levels in Hypoalbuminemia
- Assessing a Time-Dependent Enzyme Interaction
- Detecting Errors in Weight-Based and Infusion Calculations
- Choosing a Drug Monitoring Schedule
- Distinguishing Poor Adherence from Pharmacological Failure
- Explaining Model Assumptions and Remaining Uncertainty
82Integrated Pharmacotherapy Case Studies15 thèmes
- Hypertension with Diabetes and Chronic Kidney Disease
- Heart Failure with Hypotension and Hyperkalemia
- Atrial Fibrillation with Competing Bleeding Risks
- Chronic Pain with Polypharmacy and Organ Dysfunction
- Depression with Insomnia and Medication Intolerance
- Epilepsy with Pregnancy Planning and Drug Interactions
- Asthma with Poor Inhaler Technique and Apparent Treatment Failure
- Bacterial Infection with Allergy History and Renal Impairment
- Immunosuppression with New Infection and Interacting Medicines
- Cancer Treatment with Multiple Supportive Medicines
- Pediatric Liquid Medicine and Dosing Error Prevention
- Frailty, Falls, and a Prescribing Cascade
- Suspected Drug-Induced Liver Injury
- Medication Reconciliation After a Complex Hospital Admission
- Deprescribing When Treatment Goals Change
83Integrated Pharmacology and Therapeutics Capstone12 thèmes
- Defining a Patient-Centered Therapeutic Problem
- Building an Accurate Medication and Exposure History
- Selecting Relevant Mechanistic and Clinical Evidence
- Comparing Reasonable Treatment Options
- Designing an Individualized Medication Regimen
- Checking Interactions, Contraindications, and Practical Feasibility
- Establishing Efficacy and Safety Monitoring
- Preparing a Clear Medication Explanation for the Patient
- Planning for Nonresponse, Toxicity, and Changing Circumstances
- Defining Review, Switching, and Discontinuation Criteria
- Documenting and Defending the Therapeutic Rationale
- Revising the Plan After New Clinical Information
Quinze minutes.Chaque jour.
- 1
Une leçon tient dans une pause déjeuner
Une idée à la fois, en diapositives courtes. Une leçon entière prend environ quinze minutes.
- 2
Des exercices corrigés à l'instant
Les questions sont dans la leçon. Répondez et voyez tout de suite si c'est juste.
- 3
Une série qui donne envie de revenir
Une leçon par jour entretient la série. De petites séances régulières vous mènent au bout.
- 1
Une leçon tient dans une pause déjeuner
Une idée à la fois, en diapositives courtes. Une leçon entière prend environ quinze minutes.
- 2
Des exercices corrigés à l'instant
Les questions sont dans la leçon. Répondez et voyez tout de suite si c'est juste.
- 3
Une série qui donne envie de revenir
Une leçon par jour entretient la série. De petites séances régulières vous mènent au bout.
Pour qui vérifie la dose.
Étudiants en pharmacie avant leurs examens
Là où vous progresserez le plus
Calculez les doses à partir de données pharmacocinétiques
Étape 1 · Drug Action & PharmacokineticsInfirmiers qui accèdent à la prescription
Là où vous progresserez le plus
Repérez les interactions avant qu'elles n'atteignent le patient
Étape 2 · Safety, Evidence & PopulationsÉtudiants en médecine qui veulent que ça reste
Là où vous progresserez le plus
Construisez des traitements pour maladies cardiaques et métaboliques
Étape 4 · Organ-System Therapeutics
Où mène ce cours.
Le métier autour duquel ce cours est construit, et comment on y entre.
Clinical Research Associate
Surveille les essais cliniques pour que les données soient fiables et les patients protégés.
Toutes les carrières d'avenirAu quotidien
- Se rendre sur les sites d'essai et vérifier les données par rapport aux documents sources
- S'assurer qu'un essai respecte son protocole et la réglementation
- Suivre les événements de sécurité et les déclarer dans les délais
Comment y entrer
En général un diplôme en sciences de la vie, en pharmacie ou en soins infirmiers ; beaucoup commencent comme assistants d'essais ou coordinateurs de site.
Soyez parmi les premiers.
Accès anticipé pour les particuliers, pilotes pour les équipes. Dites-nous qui va apprendre.
enterprise@astratrainer.com